Several brokerages have updated their recommendations and price targets on shares of Ovid Therapeutics (NASDAQ: OVID) in the last few weeks: 2/8/2020 – Ovid Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing […]
